Literature DB >> 32215616

5-Azacitidine in patients with IDH1/2-mutant recurrent glioma.

Laetitia Federici1, Laurent Capelle2, Maxime Annereau1, Franck Bielle3, Christophe Willekens4,5, Caroline Dehais6, Florence Laigle-Donadey6, Khê Hoang-Xuan6, Jean-Yves Delattre6, Ahmed Idbaih6, Francois Lemare1, Stéphane de Botton4,5, Marc Sanson6, Mehdi Touat6,7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32215616      PMCID： PMC7594550          DOI： 10.1093/neuonc/noaa074

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   13.029


× No keyword cloud information.
  10 in total

1.  Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellström-Lindberg; Valeria Santini; Norbert Gattermann; Ulrich Germing; Guillermo Sanz; Alan F List; Steven Gore; John F Seymour; Hervé Dombret; Jay Backstrom; Linda Zimmerman; David McKenzie; C L Beach; Lewis R Silverman
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

2.  International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.

Authors:  Hervé Dombret; John F Seymour; Aleksandra Butrym; Agnieszka Wierzbowska; Dominik Selleslag; Jun Ho Jang; Rajat Kumar; James Cavenagh; Andre C Schuh; Anna Candoni; Christian Récher; Irwindeep Sandhu; Teresa Bernal del Castillo; Haifa Kathrin Al-Ali; Giovanni Martinelli; Jose Falantes; Richard Noppeney; Richard M Stone; Mark D Minden; Heidi McIntyre; Steve Songer; Lela M Lucy; C L Beach; Hartmut Döhner
Journal:  Blood       Date:  2015-05-18       Impact factor: 22.113

3.  Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

Authors:  Marc Sanson; Yannick Marie; Sophie Paris; Ahmed Idbaih; Julien Laffaire; François Ducray; Soufiane El Hallani; Blandine Boisselier; Karima Mokhtari; Khe Hoang-Xuan; Jean-Yves Delattre
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

4.  Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide.

Authors:  Alex Shimura Yamashita; Marina da Costa Rosa; Alexandra Borodovsky; William T Festuccia; Timothy Chan; Gregory J Riggins
Journal:  Neuro Oncol       Date:  2019-02-14       Impact factor: 12.300

5.  Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia.

Authors:  Ashkan Emadi; Rawan Faramand; Brandon Carter-Cooper; Seda Tolu; Laurie A Ford; Rena G Lapidus; Meir Wetzler; Eunice S Wang; Arash Etemadi; Elizabeth A Griffiths
Journal:  Am J Hematol       Date:  2015-02-27       Impact factor: 13.265

6.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.

Authors:  Sevin Turcan; Daniel Rohle; Anuj Goenka; Logan A Walsh; Fang Fang; Emrullah Yilmaz; Carl Campos; Armida W M Fabius; Chao Lu; Patrick S Ward; Craig B Thompson; Andrew Kaufman; Olga Guryanova; Ross Levine; Adriana Heguy; Agnes Viale; Luc G T Morris; Jason T Huse; Ingo K Mellinghoff; Timothy A Chan
Journal:  Nature       Date:  2012-02-15       Impact factor: 69.504

7.  Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.

Authors:  Sevin Turcan; Armida W M Fabius; Alexandra Borodovsky; Alicia Pedraza; Cameron Brennan; Jason Huse; Agnes Viale; Gregory J Riggins; Timothy A Chan
Journal:  Oncotarget       Date:  2013-10

8.  Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature.

Authors:  Charles F Craddock; Aimee E Houlton; Lynn Swun Quek; Paul Ferguson; Emma Gbandi; Corran Roberts; Marlen Metzner; Natalia Garcia-Martin; Alison Kennedy; Angela Hamblin; Manoj Raghavan; Sandeep Nagra; Louise Dudley; Keith Wheatley; Mary Frances McMullin; Srinivas P Pillai; Richard J Kelly; Shamyla Siddique; Michael Dennis; Jamie D Cavenagh; Paresh Vyas
Journal:  Clin Cancer Res       Date:  2017-08-01       Impact factor: 12.531

9.  Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents.

Authors:  Courtney D DiNardo; Keyur P Patel; Guillermo Garcia-Manero; Rajyalakshmi Luthra; Sherry Pierce; Gautam Borthakur; Elias Jabbour; Tapan Kadia; Naveen Pemmaraju; Marina Konopleva; Stefan Faderl; Jorge Cortes; Hagop M Kantarjian; Farhad Ravandi
Journal:  Leuk Lymphoma       Date:  2014-02-04

Review 10.  IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives.

Authors:  Johanna Mondesir; Christophe Willekens; Mehdi Touat; Stéphane de Botton
Journal:  J Blood Med       Date:  2016-09-02
  10 in total
  8 in total

Review 1.  Targeting IDH-Mutant Glioma.

Authors:  Julie J Miller
Journal:  Neurotherapeutics       Date:  2022-04-27       Impact factor: 7.620

Review 2.  Systematic Review of Epigenetic Therapies for Treatment of IDH-mutant Glioma.

Authors:  Vaidya Govindarajan; Ashish H Shah; Long Di; Sarah Rivas; Robert K Suter; Daniel G Eichberg; Evan Luther; Victor Lu; Alexis A Morell; Michael E Ivan; Ricardo J Komotar; Nagi Ayad; Macarena De La Fuente
Journal:  World Neurosurg       Date:  2022-03-18       Impact factor: 2.210

3.  Viability fingerprint of glioblastoma cell lines: roles of mitotic, proliferative, and epigenetic targets.

Authors:  Darja Lavogina; Tõnis Laasfeld; Markus Vardja; Helen Lust; Jana Jaal
Journal:  Sci Rep       Date:  2021-10-13       Impact factor: 4.379

Review 4.  Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations.

Authors:  Pasquale Persico; Elena Lorenzi; Agnese Losurdo; Angelo Dipasquale; Antonio Di Muzio; Pierina Navarria; Federico Pessina; Letterio Salvatore Politi; Giuseppe Lombardi; Armando Santoro; Matteo Simonelli
Journal:  Cancers (Basel)       Date:  2022-02-22       Impact factor: 6.639

Review 5.  From Metabolism to Genetics and Vice Versa: The Rising Role of Oncometabolites in Cancer Development and Therapy.

Authors:  Emanuela Di Gregorio; Gianmaria Miolo; Asia Saorin; Agostino Steffan; Giuseppe Corona
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

Review 6.  Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.

Authors:  Maria B Garcia-Fabiani; Santiago Haase; Andrea Comba; Stephen Carney; Brandon McClellan; Kaushik Banerjee; Mahmoud S Alghamri; Faisal Syed; Padma Kadiyala; Felipe J Nunez; Marianela Candolfi; Antonela Asad; Nazareno Gonzalez; Marisa E Aikins; Anna Schwendeman; James J Moon; Pedro R Lowenstein; Maria G Castro
Journal:  Front Oncol       Date:  2021-06-08       Impact factor: 5.738

Review 7.  The role of human endogenous retroviruses in gliomas: from etiological perspectives and therapeutic implications.

Authors:  Ashish H Shah; Mark Gilbert; Michael E Ivan; Ricardo J Komotar; John Heiss; Avindra Nath
Journal:  Neuro Oncol       Date:  2021-10-01       Impact factor: 13.029

Review 8.  IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment.

Authors:  Lidia Gatto; Enrico Franceschi; Alicia Tosoni; Vincenzo Di Nunno; Ilaria Maggio; Raffaele Lodi; Alba Ariela Brandes
Journal:  Mol Diagn Ther       Date:  2021-06-07       Impact factor: 4.476
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.